SBFM Sunshine Biopharma Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1402328 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-5.2%
TTM net income YoY-3.0%
TTM EPS YoY—
Revenue 3-yr CAGR20.2%
Net income 3-yr CAGR—
Margins
Gross margin30.4%
Operating margin-17.2%
Net margin-17.5%
FCF margin—
EBITDA margin-16.3%
Returns
ROE-23.4%
ROA-18.9%
ROIC (approx.)-33.3%
Asset turnover1.08x
Leverage & solvency
Liabilities / assets15.4%
Debt / equity0.00x
Current ratio6.47x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-0.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $36.31M | $34.87M |
| Cost of revenue | $24.05M | $24.20M |
| Gross profit | $12.26M | $10.67M |
| R&D expense | $604,308 | $933,902 |
| SG&A expense | $18.48M | $16.48M |
| Operating income | -$6.23M | -$5.81M |
| Interest expense | $0 | $8,774 |
| Pretax income | -$5.95M | -$5.37M |
| Income tax | $21,609 | -$234,858 |
| Net income | -$5.98M | -$5.13M |
| EBITDA | -$5.89M | -$5.59M |
| EPS (basic) | -1.44 | -7.32 |
| EPS (diluted) | — | -7.32 |
| Weighted avg. shares (diluted) | — | 701,749 |
| Balance sheet | ||
| Cash & equivalents | $9.12M | $9.69M |
| Receivables | $3.46M | $3.87M |
| Inventory | $13.47M | $11.28M |
| Current assets | $26.85M | $25.97M |
| PP&E, net | $557,370 | $546,055 |
| Goodwill | — | $0 |
| Intangibles | $1.89M | $3.02M |
| Total assets | $30.08M | $30.56M |
| Current liabilities | $6.44M | $6.31M |
| Total liabilities | $7.04M | $7.06M |
| Shareholders' equity | $23.04M | $23.50M |
| Shares outstanding | 24,530 | 2.58M |
| Cash flow statement | ||
| Operating cash flow | -$5.33M | -$12.52M |
| Capital expenditure | $174,491 | $1.66M |
| Free cash flow | -$5.51M | -$14.18M |
| Investing cash flow | -$836,306 | -$1.98M |
| Financing cash flow | $4.75M | $8.94M |
| Depreciation & amortization | $332,070 | $223,527 |
| Share buybacks | $0 | $3.14M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.